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ABSTRACT
Objective: Swertiamarin, a secoiridoid glycoside present in the leaves of Enicostemma littorale, is reported to be responsible for its pharmacological 
and beneficial properties. The present study was aimed to biochemically evaluate the antidiabetic properties of Swertiamarin in high fat diet fed - low 
dose streptozotocin (STZ)-treated diabetic rats.
Methods: High-fat diet-fed low-dose STZ was used to induce experimental type 2 diabetes in rats. Diabetic rats were orally treated with swertiamarin 
(50 mg/kg b.w./rat/day) for 30 days. The physiological criterions such as food and fluid intake were recorded. Oral glucose tolerance test was 
performed. The levels of fasting blood glucose, plasma insulin, glycosylated hemoglobin A1c (HbA1c), hemoglobin, and homeostasis model assessment 
of insulin resistance (HOMA-IR) values were estimated. The activities of key enzymes involved in carbohydrate and glycogen metabolism in the liver 
and kidney tissues were assayed. The glycogen content in liver tissue was estimated.
Result: Oral administration of swertiamarin to diabetic rats established a significant decline in the levels of fasting blood glucose, HbA1c as well 
as HOMA-IR values and an increase in plasma insulin and hemoglobin levels. The altered activities of key enzymes of carbohydrate and glycogen 
metabolism in liver and kidney tissues of diabetic rats were restored to near normalcy by swertiamarin treatment.
Conclusion: Swertiamarin treatment maintains normoglycemia in diabetic rats by modulating the activities of key carbohydrate and glycogen 
metabolizing enzymes in the hepatic and renal tissues.
Keywords: Swertiamarin, High-fat diet, Streptozotocin, Antidiabetic property.
INTRODUCTION
Last few decades witnessed a rapid increase in the incidence of diabetes 
mellitus due to increased socioeconomic developments in many parts of 
the world. Type 2 diabetes mellitus (T2DM) accounts for more than 90% 
of the diabetic population globally and is chiefly manifested by insulin 
resistance which in turn arises due to obesity. The influence of obesity 
and other contributing factors in inducing T2DM has been reported in 
many studies around the world. Its incidence is increasing alarmingly 
owing to genetic and environmental factors which ultimately results in 
decreased insulin synthesis, impaired regulation of glucose metabolism, 
and pancreatic β-cell dysfunction. Obesity and insulin resistance have 
been found to play an integral role in the initiation and progression of 
T2DM. Insufficient insulin secretion results in reduced glucose transport 
into the vital organs such as liver, muscle, and adipose tissues [1]. 
In the initial stages of diabetes mellitus, the chronic hyperglycemia 
induces excessive secretion of insulin leading to hyperinsulinemia and 
subsequently to hypoinsulinemia [2]. The chronic hyperglycemia is 
reported to play a pivotal role in all forms of secondary complications of 
diabetes. The onset of T2DM is progressive, and it involves glucotoxicity 
and lipotoxicity commonly known as glucolipotoxicity [3].
Glucose is a principal source of energy for all cells and organs. However, 
chronic elevation of its levels results in diabetes and its secondary 
complications. Blood glucose levels should be maintained within the 
physiological range. The liver plays an important role in buffering the 
blood glucose level by contributing either hepatic glucose utilization or 
hepatic glucose production (HGP) depending on the prevailing plasma 
glucose level to maintain the critical threshold value of ∼6 mM. The 
hepatocytes are equipped with an array of regulatory mechanisms 
to control the process of glycogenesis, glycogenolysis, glycolysis, 
and gluconeogenesis [4,5]. There are several options to maintain 
normoglycemia in diabetic individuals. However, most of the currently 
available antidiabetic medications elicit undesirable side effects and 
diminution in response after prolonged use [6]. Hence, search for 
newer drugs has become a continuous process and the medicinal plants 
serve as a major source of drug discovery.
Among the various medicinal plants which have been traditionally 
used for the treatment of diabetes, Enicostemma littorale Blume 
which belongs to the family of Gentianaceae plays an imperative role. 
The leaf extract is used in reducing obesity and improving the liver 
functions [7]. Swertiamarin, a secoiridoid glycoside, originally isolated 
from the leaves of E. littorale and was reported to be responsible for the 
medicinal properties of E. littorale. It forms as an important constituent 
of many herbal preparations in Japan [8,9].
Li et al. reported the absorption, distribution, and elimination 
pattern of swertiamarin [10]. Several reports are available in the 
literature regarding the pharmacological properties of swertiamarin. 
However, most of the reports are pertaining to in vitro experiments 
only. Further, the mechanism of action of swertiamarin has not been 
explored at a systemic level [11,12]. More recently, we have reported 
the phytochemical analysis and antioxidant potentials of E. littorale 
leaf extract [13]. In the absence of systemic studies in the literature 
pertaining to the antidiabetic properties of swertiamarin, in the present 
study, an attempt has been made to evaluate the antidiabetic property of 
swertiamarin in HFD–fed low-dose STZ-induced type 2 diabetes in rats.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i10.28152
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MATERIALS AND METHODS
Chemicals
Streptozotocin (STZ) and swertiamarin were procured from Sigma 
Aldrich, stored at 2°C to 4°C, and protected from light. All other 
chemicals used in the present study were purchased from standard 
commercial suppliers and were of analytical grade quality.
Acute toxicity and dosage fixation studies
Acute toxicity studies were performed as per the OECD guidelines (423) 
for testing of chemicals in normal rats. Graded doses of swertiamarin 
dissolved in 0.2% dimethyl sulfoxide were administered orally. The 
rats were observed for 4 weeks following oral administration. The 
changes in food consumption, fluid intake, psychomotor activities, 
changes in body weight gain, and changes in skin, fur, eyes, salivation, 
diarrhea, and lethargy were consistently monitored. Macroscopic 
examination of vital organs was also performed. Similarly, the dosage 
fixation studies were carried out by administering graded doses of 
swertiamarin (5, 10, 20, 25, and 50 mg/kg b.w./rat/day) for 30 days 
to determine the dose-dependent hypoglycemic effect in HFD-fed low-
dose STZ-induced diabetic rats by monitoring the fasting blood glucose 
levels periodically.
Experimental animals
Male Wistar Albino rats weighing about 160–180 g, procured from 
Tamilnadu Veterinary and Animal Sciences University, Chennai, India, 
were housed in clean, sterile, polypropylene cages under standard 
vivarium conditions (12 h light/dark cycle) and temperature (25±2°C) 
with ad libitum access to water and standard rat chow (Hindustan 
Lever Ltd., Bengaluru, India) with a composition of 5% fat, 21% protein, 
55% nitrogen-free extract, and 4% fiber (w/w) with adequate minerals 
and vitamins for the animals. The animals were acclimatized to the 
laboratory conditions for 2 weeks before the inception of experiments. 
The studies were conducted strictly according to the rules and norms 
stipulated by the Institutional Animal Ethics Committee Guidelines.
High-fat diet (HFD)-fed low-dose STZ-induced diabetes
The rats were divided into two dietary regimens by feeding either 
normal or HFD for the initial period of 2 weeks [14]. The ingredients 
and chemical composition of the HFD was followed and is mentioned 
in Table 1.
After 2 weeks of dietary manipulation to develop insulin resistance, the 
groups of rats fed with HFD were intraperitoneally injected with a freshly 
prepared low dose of STZ (35 mg/kg b.w) dissolved in 0.1 M ice-cold 
citrate buffer, pH 4.5. 3 days after injection with STZ, the experimental 
rats were screened for fasting blood glucose level. Experimental rats 
which show the fasting blood glucose above 250 mg/dl were chosen 
for further studies. The rats were allowed to continue to feed on the 
respective diets until the end of the experiments.
EXPERIMENTAL PROTOCOL
The rats were divided into four groups each group comprising six rats.
 Group 1: Control rats
 Group 2: Diabetic rats (HFD low-dose STZ; 35 mg/kg b.w.)
 Group 3: Diabetic rats treated with swertiamarin (50 mg/kg b.w.)
 Group 4: Diabetic rats treated with metformin (50 mg/kg b.w.).
During the experimental period, body weight, blood glucose, food 
and water consumption, and physical examinations were determined 
at regular intervals. The dosage was adjusted every week according 
to any change in body weight to maintain similar dose per kg body 
weight of rat over the entire period of study for each group. At the end 
of the treatment period, the rats were fasted overnight, anesthetized 
(ketamine, 80 mg/kg b.w., i.p.), and sacrificed by cervical decapitation. 
The blood was collected with or without anticoagulants for plasma or 
serum separation, respectively. The liver, kidney, and pancreatic tissues 
were dissected out and washed in ice-cold saline and used for further 
experimental studies.
Oral glucose tolerance test (OGTT)
On the day before sacrifice, an OGTT was performed in all the groups. 
Blood samples were obtained from the lateral tail vein of rats deprived 
of food overnight. Successive blood samples were taken at 0, 30, 60, 90, 
and 120 min following the oral administration of 2 g/kg b.w. of glucose 
solution.
Homeostasis model assessment of insulin resistance (HOMA-IR)
Insulin resistance was evaluated by HOMA-IR by the method of 
Matthews et al. [15], as follows:
( )
( )
µFasting Insulin Level U / mL  X Fasting 





The levels of blood glucose were measured by glucose oxidase 
method [16]. Plasma insulin was assayed using ELISA kit for rats 
(Linco Research, Inc., USA). The levels of hemoglobin and glycosylated 
hemoglobin A1c (HbA1c) were estimated [17,18]. Urine sugar was 
detected using urine strips.
Assay of key enzymes of carbohydrate metabolism
A portion of the liver and kidney tissues was dissected, washed 
immediately with ice-cold saline, and homogenized in 0.1 M Tris–
HCl buffer (pH 7.4) for the assay of key enzymes of carbohydrate 
metabolism. The debris was removed by centrifugation at 10,000 rpm, 
and the supernatant was used for the assay of hexokinase, pyruvate 
kinase (PK), lactate dehydrogenase (LDH), glucose-6-phosphatase, 
fructose-1,6-bisphosphatase, glucose-6-phosphate dehydrogenase, 
glycogen synthase, and glycogen phosphorylase activity [19-26]. 
Glycogen content was estimated in wet liver tissue [27].
Statistical analysis
The results were expressed as mean ± SEM of six rats in each group, 
and the statistical significance was evaluated by one-way Analysis Of 
Variance (ANOVA) using the SPSS (version 16) program followed by 
least significant difference (LSD). Values were considered statistically 
significant when p<0.05.
RESULTS
The levels of food and fluid intake in control and experimental groups of 
rats are shown in Figs. 1 and 2, respectively. HFD-STZ-induced diabetic 
rats showed a significant (p<0.05) increase in food and fluid intake 
when compared with the control group of rats. On oral administration 
of swertiamarin to the diabetic group of rats, the levels were found 
to be similar to that of the control group of rats, and the efficacy was 
comparable with metformin.
The levels of blood glucose in certain specific durations after the oral 
administration of glucose (2 g/kg b.w.) in control and the experimental 
group of rats are depicted in Fig. 3. In control group of rats, the blood 
glucose level reached the maximum peak at 60 min after an oral glucose 
load, and then, it was gradually reverted back to near normal levels 
Table 1: Composition of the high fat diet
Ingredients Diet (g/kg)




Vitamin and mineral mix 60 
DL-methionine 03 
Yeast powder 01 
Sodium chloride 01 
*The composition of normal pellet diet (NPD): 4.1% fat, 22.2% protein, and 
12.1% carbohydrates, as a percentage of total kilocal
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after 120 min indicating the maintenance of normoglycemia, whereas 
in the case of STZ-induced diabetic group of rats, the peak increase in 
blood glucose concentration was observed after 60 min and remained 
high over the next 60 min. Oral administration of swertiamarin, as well 
as metformin to HFD-STZ, induced diabetic rats showed a significant 
decrease in blood glucose concentration at 60 and 120 min when 
compared with the diabetic group of rats.
Fig. 4 represents the homeostatic assessment of insulin resistance 
(HOMA-IR) in the control and experimental groups of rats. A significant 
elevation in HOMA-IR values was observed in the diabetic group of rats. On 
oral administration of swertiamarin, HOMA-IR values were significantly 
decreased, and the effect was found to be comparable with metformin.
The effect of oral administration of swertiamarin on the levels of fasting 
blood glucose, plasma insulin, and HbA1c in HFD-fed low-dose STZ-
induced experimental type 2 diabetic rats is presented in Table 2. In 
the diabetic group of rats, the levels of fasting blood glucose and HbA1c 
were significantly increased with a concomitant decrease in the levels 
of plasma insulin and hemoglobin. Treatment with swertiamarin 
significantly decreased the altered levels of fasting blood glucose and 
HbA1c in diabetic groups of rats. The plasma insulin and hemoglobin 
levels were improved to the physiological range on oral administration 
with swertiamarin for 30 days.
The activities of regulatory enzymes such as hexokinase, PK, and LDH 
in liver and kidney tissues of control and experimental groups of rats are 
presented in Tables 3 and 4. It is evident from the data that the activities of 
both hexokinase and PK were significantly decreased in the hepatic tissue of 
diabetic rats. Swertiamarin treatment modulates the activity of the enzymes 
in hepatic tissues of HFD-fed STZ-induced diabetic rats. The activity of LDH 
in diabetic rats was significantly elevated when compared to control rats. 
Altered activity of LDH in diabetic rats is reverted to near normal values on 
oral administration with swertiamarin as well as metformin.
Tables 5 and 6 depict the activities of glucose-6-phosphatase, 
fructose-1, 6-bisphosphatase, and glucose-6-phosphate dehydrogenase 
in liver and kidney tissues of control and experimental groups of rats. 
Experimental type 2 diabetic rats showed significantly increased 
activities of glucose-6-phosphatase and fructose-1, 6-bisphosphatase. 
The activity of glucose-6-phosphate dehydrogenase was significantly 
decreased in diabetic rats. These altered activities were bringing back 
to normal levels by oral administration of Swertiamarin. Metformin-
treated diabetic rats also exhibit similar results.
Table 7 shows the level of liver glycogen and the activities of glycogen 
synthase and glycogen phosphorylase in control and experimental 
Fig. 1: Effect of swertiamarin on food intake of experimental 
groups of rats. Values are given as mean±SEM for groups of six 
rates in each. One-way ANOVA followed by post-hoc test LSD. 
Values are statistically significant at @p<0.05; dare compared with 
acontrol rats, bdiabetic control rats, units: Food intake - g/rat/day. 
SEM: Standard error mean, LSD: Least significant difference
Fig. 2: Effect of Swertiamarin on water intake of experimental 
groups of rats. Values are given as mean±SEM for groups of six 
rates in each. One-way ANOVA followed by post-hoc test LSD. 
Values are statistically significant at @p<0.05, dare compared with 
acontrol rats, bdiabetic control rats, units: Water intake - ml/rat/
day. SEM: Standard error mean, LSD: Least significant difference
Fig. 3: Oral glucose tolerance test of control and experimental 
groups of rats. Values are given as mean±SEM for groups of six 
rates in each. One-way ANOVA followed by post-hoc test LSD. 
Values are statistically significant at @p<0.05, dare compared with 
acontrol rats, bdiabetic control rats. SEM: Standard error mean, 
LSD: Least significant difference
Fig. 4: Homeostasis model assessment of insulin resistance 
of control and experimental groups of rats. Values are given 
as mean±SEM for groups of six rates in each. One-way ANOVA 
followed by post-hoc test LSD. Values are statistically significant at 
@p<0.05, dare compared with acontrol rats, bdiabetic control rats. 
SEM: Standard error mean, LSD: Least significant difference
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groups of rats. Diabetic rats showed a considerable decrease in the liver 
glycogen content and glycogen synthase activity and a concomitant 
increase in glycogen phosphorylase activity. Oral administration of 
swertiamarin to the diabetic group of rats restored the level of liver 
glycogen and the activities of glycogen synthase, as well as glycogen 
phosphorylase, were brought back to physiological levels.
DISCUSSION
Phytotherapy continues to show a better complimentary potential 
in the treatment of various free radical-mediated diseases such as 
diabetes and cancer. The bioactive principles present in various parts of 
plants serve as potential antioxidants in preventing and/or protecting 
against several diseases in humans [28]. Phytochemicals derived from 
medicinal plants are widely used as raw materials for drug development. 
However, only a few traditionally important medicinal plants have 
been subjected to pharmacological scrutiny. One such phytochemical 
which lacks scientific validation for its traditional beneficial and 
pharmacological properties is Swertiamarin, a secoiridoid glycoside 
originally isolated from the leaves of E. littorale.
Feeding with HFD is routinely used to develop insulin resistance in 
experimental animals [29-32]. Administration of low dose of STZ 
(35 mg/kg b.w.) to HFD-fed rats causes partial destruction of pancreatic 
β-cells by necrosis, resulting in insulin deficiency [33]. Srinivasan et al. 
reported that the combination of HFD-fed and low-dose STZ-treated 
rats serve an alternative animal model simulating the natural disease 
progression and metabolic characteristics of type 2 diabetes, and the 
model is widely used to screen the therapeutic potential of compounds 
exhibiting insulin-sensitizing and secretory effects.
Type 2 diabetes induced by high-fat diet is associated with obesity, 
hyperglycemia, and hyperinsulinemia which induces β-cell dysfunction 
and excessive generation of free radicals [34]. β-cell dysfunction and 
insulin resistance are intrinsically complex with their interrelation for 
inducing the pathogenesis of type 2 diabetes. An increase in the delivery 
of free fatty acids reduces the ability of the insulin receptor substrates 
to activate phosphoinositide 3-kinase (PI 3-kinase) which results in 
the diminution of glucose transport and other events downstream of 
insulin receptor signaling [35]. HFD causes increased generation of 
Table 2: The levels of blood glucose, hemoglobin, HbA1c, plasma insulin, and urine sugar in control and experimental groups of rats
Groups Blood glucose Hemoglobin HbA1c Insulin Urine sugar
Control 92.50±3.17 12.40±0.27 6.11±0.21 16.30±0.45 Nil
Diabetic 288.33±9.33a* 10.40±0.43a* 13.60±0.32a* 5.52±0.26a* +++
Diabetic+swertiamarin 138.00±5.25b* 13.11±0.28b* 7.80±0.24b* 8.20±0.43b* Nil
Diabetic+metformin 128.50±4.00b* 12.43±0.49b* 7.21±0.22b* 9.40±0.48b* Nil
Units: mg/dl for blood glucose, g/dl for hemoglobin, % hemoglobin for HbA1c, µU/ml for plasma insulin, +++indicates more than 2% sugar. Results are expressed as 
mean±SEM (n=6). One-way ANOVA followed by post‑hoc test LSD. Values are statistically significant at *p<0.05. The results were compared with acontrol rats, bdiabetic 
rats. SEM: Standard error mean, LSD: Least significant difference, HbA1c: Glycosylated hemoglobin A1c
Table 3: Effect of swertiamarin on the activities of hexokinase and PK in liver tissues of control and experimental groups of rats
Groups Hexokinase PK LDH
Control 279.62±8.33 230.00±9.02 209.00±3.03
Diabetic 150.23±7.03a* 123.80±4.42a* 532.25±33.24a*
Diabetic+swertiamarin 216.10±9.68b* 185.40±6.32b* 300.50±5.10b*
Diabetic+metformin 232.82±9.52b* 176.10±5.20b* 279.10±2.30b*
Units are expressed as: µmoles of glucose-6-phosphate formed/h/mg of protein for hexokinase, mU/mg of protein for PK. Values are given as mean±SEM (n=6) for 
groups of six rats in each. One-way ANOVA followed by post‑hoc test LSD. Statistical significance was compared within the groups as follows: aControl rats; bdiabetic 
control rats; Values are statistically significant at *p<0.05. SEM: Standard error mean, LSD: Least significant difference, PK: Pyruvate kinase, LDH: Lactate dehydrogenase
Table 4: Effect of swertiamarin on the activities of hexokinase and PK in kidney tissues of control and experimental groups of rats
Groups Hexokinase PK LDH
Control 152.50±5.00 175.00±7.80 510.15±15.00
Diabetic 83.27±5.00a* 100.00±5.50a* 729.10±24.10a*
Diabetic+swertiamarin 114.40±6.60b* 135.00±8.40b* 550.20±20.21b*
Diabetic+metformin 123.00±5.60b* 142.50±6.70b* 542.00±21.32b*
Units are expressed as: µmoles of glucose-6-phosphate formed/h/mg of protein for hexokinase, mU/mg of protein for PK, µ moles of pyruvate formed/h/mg 
of protein for lactate dehydrogenase. Values are given as mean±SEM for groups of six rats in each. One-way ANOVA followed by post‑hoc test LSD. Statistical 
significance was compared within the groups as follows: aControl rats; bdiabetic control rats. Values are statistically significant at *p<0.05. SEM: Standard error mean, 
LSD: Least significant difference, PK: Pyruvate kinase, LDH: Lactate dehydrogenase
Table 5: Activities of glucose-6-phosphatase, fructose-1, 6-bisphosphatase, and glucose-6-phosphate dehydrogenase in liver tissues of 
control and experimental groups of rats
Groups Glucose-6-phosphatase Fructose-1,6-bisphosphatase Glucose-6-phosphate dehydrogenase
Control 873.30±29.20 354.00±16.05 483.00±29.33
Diabetic 1580.40±68.80a* 833.20±34.08a* 265.10±16.20a*
Diabetic+swertiamarin 1050.29±43.00b* 468.72±25.70b* 392.42±20.20b*
Diabetic+metformin 1100.10±50.8b* 460.50±20.50b* 350.50±22.80b*
Units are expressed as: µmoles of Pi liberated/h/mg of protein for glucose-6-phosphatase and fructose-1, 6-bisphosphatase and µmoles of NADPH/min/mg of protein 
for glucose-6-phosphate dehydrogenase. Values are given as mean±SEM for groups of six rats in each. One-way ANOVA followed by post‑hoc test LSD. Statistical 
significance was compared within the groups as follows: acontrol rats; bdiabetic control rats. Values are statistically significant at *p<0.05. SEM: Standard error mean, 
LSD: Least significant difference
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reactive oxygen species, decreased mitochondrial function and closed 
calcium channel leading to decreased ATP synthesis, impaired glucose 
homeostasis, and ultimately β-cell dysfunction and death [36].
Diabetes mellitus is associated with loss of body weight, polyuria, 
polydipsia, and polyphagia. Impaired hepatic energy metabolism 
and a low energy state stimulate satiety center and increase food 
intake in T2DM [37]. Hepatic energy state has an influence on feeding 
behavior which in turn regulates body weight [38]. Initially, the rats 
fed with HFD for 2 weeks showed an increase in body weight due to 
the deposition of fat pads. Although the food intake of diabetic rats 
was increased during the entire experimental period, the weight gain 
was not statistically significant. The impaired glycemic control and 
unavailability of carbohydrate for energy production result in excessive 
catabolism of proteins to provide amino acids for gluconeogenesis, and 
this leads to muscle wasting and weight loss during insulin deficiency 
in diabetic rats [39]. Osmotic diuresis increases fluid intake in diabetic 
rats when compared to normal rats. However, oral administration of 
swertiamarin significantly normalized food and fluid intake suggesting 
an improvement in glycemic control in diabetic-treated rats.
OGTT measures the body’s ability to utilize glucose, the body’s main 
source of energy. An OGTT is a more sensitive measure of early 
abnormalities in glucose regulation than fasting plasma glucose [40]. 
OGTT is a primary test of immense value, in which the fasting plasma 
glucose concentration is estimated quantitatively to diagnose diabetes 
mellitus. Impaired glucose tolerance reflects increased hepatic 
gluconeogenesis and reduced uptake of glucose from the blood into 
skeletal muscle and adipose tissue following a meal [41]. The impaired 
glucose tolerance observed in the diabetic group of rats was altered 
to near normal by the treatment with swertiamarin which indicates 
the blood glucose lowering effect of Swertiamarin. Our results are in 
accordance with the findings of Patel et al. [42].
Blood glucose is a biochemical index for the diagnosis and prognosis 
of diabetes mellitus. In the present study, oral administration of 
swertiamarin decreased the levels of blood glucose and improved 
insulin sensitivity in HFD-STZ diabetic rats. The levels of plasma insulin 
were moderately decreased in experimental diabetic rats. Although 
the level was not decreased significantly, the insulin level in HFD-STZ 
diabetic rats could not stimulate glucose uptake into the cells due to the 
development of insulin-resistant state. There were an improved insulin 
sensitivity and a rise in insulin level in Swertiamarin-treated diabetic 
rats, suggesting that swertiamarin administration improved the 
insulin-sensitizing effect as well as improved glucose tolerance which 
may be probably due to improved pancreatic β-cell mass and function. 
The absence of sugar in the urine samples of swertiamarin-treated rats 
evidenced its renoprotective effect. The degree of hyperinsulinemia 
and insulin resistance was evidenced by fasting insulin levels and 
HOMA-IR. Diabetic rats exhibit severe insulin resistance and marked 
hyperglycemia. A significantly reduced HOMA-IR index in swertiamarin-
treated diabetic rats evidenced the efficacy of swertiamarin in restoring 
insulin sensitivity.
HbA1c is a reliable and reproducible biochemical parameter widely 
used to assess long-term maintenance of glycemic control. For long-
term studies pertaining to diabetic complications, HbA1c is considered 
as an advantageous tool as it is not subjected to any momentary 
changes due to stress or some other acute factor. Thus, establishing 
the relationship between HbA1c and fasting glucose is considered as 
an important factor in the assessment of glucose homeostasis over the 
past 3 months [43].
HbA1c is formed as a post-synthetic modification of HbA throughout 
the life of the red blood cells. The amount of HbA1c formed reflects the 
status of carbohydrate metabolism of an individual. In uncontrolled 
or poorly controlled diabetes, there is an increased glycosylation of a 
number of proteins including hemoglobin [44]. HbA1c was found to 
increase in mice with diabetes mellitus to approximately 16%, and the 
amount of increase is directly proportional to the fasting blood glucose 
level [45]. The levels of HbA1c strongly predict the risk of eye, kidney, 
and neural disease in diabetes mellitus and are regarded as a key target 
for the diagnosis and prognosis of diabetes-related complications [46]. 
During diabetes, the excess glucose present in the blood reacts with 
hemoglobin irreversibly. In the present study, rats treated with 
swertiamarin showed the significant reduction in the levels of HbA1c 
and an increased level of total hemoglobin in diabetic rats. This could 
be due to the beneficiary effect of swertiamarin in maintaining glucose 
homeostasis probably through the reduction of oxidative stress.
The liver plays an important role in the maintenance of normoglycemia 
by storing excessive glucose in the bloodstream and releases the 
same when the blood glucose level is physiologically low [47]. As a 
consequence of prolonged HFD feeding, the activity of enzymes involved 
Table 6: Activities of glucose-6-phosphatase, fructose-1, 6-bisphosphatase, and glucose-6-phosphate dehydrogenase in kidney tissues of 
control and experimental groups of rats
Groups Glucose-6-phosphatase Fructose-1, 6-bisphosphatase Glucose-6-phosphate dehydrogenase
Control 362.10±19.00 595.91±12.05 612.10±28.97
Diabetic 629.00±25.20a* 881.26±32.82a* 265.47±15.17a*
Diabetic+swertiamarin 470.30±19.44b* 697.48±27.39b* 407.34±19.14b*
Diabetic+metformin 451.50±19.50b* 659.34±30.16b* 415.42±29.75b*
Units are expressed as: µmoles of Pi liberated/h/mg of protein for glucose-6-phosphatase and fructose-1, 6-bisphosphatase and µmoles of NADPH/min/mg of protein 
for glucose-6-phosphate dehydrogenase. Values are given as mean±SEM for groups of six rats in each. One-way ANOVA followed by post‑hoc test LSD. Statistical 
significance was compared within the groups as follows: aControl rats, bdiabetic control rats. Values are statistically significant at *p<0.05. SEM: Standard error mean, 
LSD: Least significant difference
Table 7: Level of glycogen content and activities of glycogen synthase and glycogen phosphorylase in liver tissues of control and 
experimental groups of rats
Groups Glycogen Glycogen synthase Glycogen phosphorylase
Control 60.00±3.45 816.00±29.42 509.20±32.00
Diabetic 24.50±1.43a* 450.80±23.30a* 782.72±31.70a*
Diabetic+swertiamarin 42.60±4.00b* 708.11±28.10b* 700.50±27.00b*
Diabetic+metformin 44.29±2.60b* 680.08±28.30b* 620.01±33.10b*
Units are expressed as: mg of glucose/g wet tissue for glycogen, µmoles of UDP formed/h/mg protein for glycogen synthase, and µmoles Pi liberated/h/mg protein 
for glycogen phosphorylase. Values are given as mean±SEM for groups of six rats in each. One-way ANOVA followed by post‑hoc test LSD. Statistical significance 
was compared within the groups as follows: aControl rats; bdiabetic control rats. Values are statistically significant at *p<0.05. SEM: Standard error mean, 
LSD: Least significant difference
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in the glycolytic and pentose phosphate pathways is decreased while 
the activity of enzymes involved in gluconeogenic and glycogenolytic 
pathways is increased in the liver [48]. The reduction of HGP has 
been targeted as a strategy for diabetes treatment. The key enzymes 
that regulate carbohydrate metabolism are considered as a potential 
target for maintaining blood glucose levels. Due to STZ administration 
to HFD-fed rats, the pancreatic function is reduced to a greater extent 
and insulin is not secreted. Insulin regulates both uptake and utilization 
of glucose in target organs such as liver, kidney, skeletal muscle, and 
adipose tissue by controlling the activities of numerous metabolic 
enzymes.
Hexokinase is the key enzyme involved in the phosphorylation of 
glucose into glucose-6-phosphate [49]. Hexokinase insufficiency 
in diabetic mice could cause decreased glycolysis and decreased 
utilization of glucose for energy production. Oral administration of 
Swertiamarin to diabetic rats resulted in significant increase in the 
activity of hexokinase. The restored levels of plasma insulin and 
glucose in swertiamarin-treated HFD-STZ-induced diabetic rats may be 
attributed to the increased hepatic hexokinase activity.
PK is a ubiquitously expressed, rate-controlling, terminal glycolytic 
enzyme that catalyzes the conversion of phosphoenolpyruvate to 
pyruvate with the generation of ATP. The altered activity of PK during 
diabetic conditions could be expected to diminish the metabolism of 
glucose and ATP production. The decreased activity of PK readily 
accounts for the decreased rate of glycolysis and an increase in the 
gluconeogenic pathway which are considered as essential for the 
maintenance for normoglycemia.
LDH is a cytosolic enzyme which converts pyruvate to lactate during 
anaerobic glycolysis, which is subsequently converted to glucose 
through the gluconeogenic pathway. During diabetes mellitus, LDH 
activity was elevated due to the impairment of glucose-stimulated 
insulin secretion. Oral administration of swertiamarin, as well as 
metformin to HFD-STZ diabetic rats, showed a significant reduction in 
the LDH activity, probably due to the regulation of NAD+/NADH ratio by 
the oxidation of glucose.
Glucose-6-phosphate dehydrogenase catalyzes the rate-limiting step of 
the hexose monophosphate shunt and produces NADPH required for 
the maintenance of the levels of reduced glutathione, a non-enzymatic 
antioxidant [50]. The observed decrease in the activity of glucose-
6-phosphate dehydrogenase in the hepatic tissues of diabetic rats 
suggests a decrease in metabolism through the phosphogluconate 
oxidation pathway. In the present study, administration of swertiamarin 
significantly increased the activity of glucose-6-phosphate 
dehydrogenase in diabetic rats.
Glucose-6-phosphatase and fructose-1, 6-bisphosphatase are the 
regulatory enzymes in the gluconeogenic pathway. The pentose 
phosphate pathway (also called the phosphogluconate pathway and the 
hexose monophosphate shunt) is a process that generates NADPH and 
pentoses (5-carbon sugars). This pathway is considered as an alternative 
to the glycolytic process, and it primarily involves two phases, namely, 
oxidative and non-oxidative. In the oxidative phase, NADPH is generated 
and 5-carbon sugars are synthesized in the non-oxidative phase. The 
decrease in the activity of fructose-1, 6-bisphosphatase has been linked 
to insulin resistance and obesity in experimental animal models of 
diabetes and suggests a principal role for fructose-1, 6-bisphosphatase 
in the gluconeogenic flux. In the present study, the reduced activities 
of both glucose-6-phosphatase and fructose-1, 6-bisphosphatase in 
hepatic tissues of diabetic rats were increased on oral administration of 
swertiamarin which revealed the reduced endogenous HGP.
Liver and skeletal muscle are the primary site of glucose disposal in the 
insulin-stimulated state. Glycogen is the storable form of glucose whose 
quantity in hepatic and skeletal muscle tissue is a reflection of insulin 
activity. The synthesis and degradation of glycogen are considered 
as reciprocally regulated pathways. Under physiological conditions, 
insulin enhances intracellular glycogen deposition by stimulating 
glycogen synthase and inhibiting glycogen phosphorylase activities. In 
the present study, the administration of swertiamarin to diabetic rats 
improved the glycogen content and normalized the altered activities 
of glycogen metabolizing enzymes in both the liver tissues, which is 
due to improved glucose utilization and storage. Oral administration 
of swertiamarin to carbohydrate-challenged mice significantly 
maintains the glycemic control through the regulation of carbohydrate 
metabolizing enzymes [51].
Insulin resistance due to HFD feeding may result in inadequate glucose 
uptake and ATP synthesis in the liver cells that make them fatigue. 
In the liver, defects in insulin-stimulated hepatic glycogen synthesis 
and increased rates of hepatic gluconeogenesis are the main factors 
that contribute to insulin resistance and fasting hyperglycemia [52]. 
However, oral treatment with swertiamarin regulates the key enzymes 
of carbohydrate metabolism, thereby maintaining glucose homeostasis.
CONCLUSION
Oral treatment with swertiamarin improves glucose homeostasis and 
possesses insulin-sensitizing effect in HFD–fed STZ-induced diabetic 
rats which is evident from the results of fasting blood glucose level, 
OGTT, plasma insulin, and HOMA IR values. The results of the present 
study also established the fact that swertiamarin increased the glycogen 
content by modulating the activities of glycogen metabolizing enzymes 
suggesting the effective utilization of glucose which in turn may be due 
to improved insulin sensitivity. Oral treatment with swertiamarin to 
experimental diabetic rats significantly improved the glycemic status 
by regulating the activities of key enzymes involved in the carbohydrate 
metabolism. Further studies are in progress to understand the 
molecular mechanisms involved in the action of swertiamarin in 
improving insulin sensitivity as well as its antidiabetic properties.
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